Zhi Tong Cai Jing·2025-08-25 14:11Core Insights - Kailaiying (002821) reported a revenue of 3.188 billion RMB for the six months ending June 30, 2025, representing a year-on-year growth of 20.08% [1] - The net profit attributable to shareholders was 617 million RMB, an increase of 23.71% year-on-year, with basic earnings per share at 1.68 RMB [1] - The gross margin for the first half of 2025 was 43.26%, up by 2.03 percentage points compared to the same period last year [1] Revenue Breakdown - The small molecule CDMO business generated revenue of 2.429 billion RMB, reflecting a year-on-year growth of 12.80% [1] - The emerging business segment achieved revenue of 756 million RMB, marking a significant increase of 51.32% year-on-year [1] Operational Performance - Despite the ongoing global downturn in biopharmaceutical financing, the company demonstrated organic revenue growth and positive trends, highlighting its operational strength and solid global customer base [1] - The implementation of cost reduction and efficiency enhancement measures, along with increased delivery scale and capacity utilization in emerging businesses, contributed to a net profit growth that outpaced revenue growth by 3.63 percentage points [1]